Prognostic scores for patients with chronic myeloid leukemia under particular consideration of competing causes of death

Prognostic discrimination for early chronic phase chronic myeloid leukemia in imatinib era: comparison of Sokal, Euro, and EUTOS scores in Korean population

(2014) Seung-Ah Yahng et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

EUTOS CML prognostic scoring system predicts ELN-based ‘event-free survival’ better than Euro/Hasford and Sokal systems in CML patients receiving front-line imatinib mesylate

(2013) Burak Uz et al.   Hematology

A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions

(2013) Aurelien Latouche et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib

(2013) V S Hoffmann et al.   LEUKEMIA

Competing risks in epidemiology: possibilities and pitfalls

(2012) Per Kragh Andersen et al.   INTERNATIONAL JOURNAL OF EPIDEMIOLOGY

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

On Estimation in Relative Survival

(2011) Maja Pohar Perme et al.   BIOMETRICS

Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score

(2011) J. Hasford et al.   BLOOD

Understanding competing risks: a simulation point of view

(2011) Arthur Allignol et al.   BMC Medical Research Methodology

Recommendations to meet statistical challenges arising from endpoints beyond overall survival in clinical trials on chronic myeloid leukemia

(2011) M Pfirrmann et al.   LEUKEMIA

Regression modeling of competing risk using R: an in depth guide for clinicians

(2010) L Scrucca et al.   BONE MARROW TRANSPLANTATION

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

(2010) Hagop Kantarjian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE